| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/17/2002 | US6451523 Variant form of the receptor for the obese gene product. the invention relates to methods of detecting this receptor variant in cells and tissues of obese individuals. |
| 09/17/2002 | US6451360 Method for treating a subject afflicted with intestinal malabsorption |
| 09/17/2002 | US6451358 Composition and method for the treatment of vitiligo |
| 09/17/2002 | US6451356 Treating skin infections and endocarditis caused by streptococcus and staphylococcus |
| 09/17/2002 | US6451353 Ultrasonically dissolvin; solvent extraction from water with chloroform; degreasing; blending with acetic ether; drying with calcium chloride; filtration, suspension; injection into cartridge using epicatechin as standard |
| 09/17/2002 | US6451350 Coating with aqueous ethyl cellulose and lipophilic plasticizing diester; drying |
| 09/17/2002 | US6451345 Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration |
| 09/17/2002 | US6451343 A-(methoximino)-a-(1-azabicyclo(2.2.2)oct-3-yl)acetonitrile hydrochloride amyloid precursor protein intensifier |
| 09/17/2002 | US6451342 Core formulation comprised of troglitazone and a biguanide |
| 09/17/2002 | US6451340 Nucleotide analog compositions |
| 09/17/2002 | US6451339 Drug delivery |
| 09/17/2002 | US6451336 Method for increasing brown fat, comprising administering conjugated linoleic acid as active ingredient |
| 09/17/2002 | US6451334 Pulse administering of a c1-c4 substituted and/or phenyl substituted carboxylic acid and salts and a carrier or diluent to stimulate cells in treating blood disorders, e.g. sickle cell anemia, thalassemia, blood loss etc. |
| 09/17/2002 | US6451303 Method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels in a human patient in need of treatment for coronary artery disease an effective amount of a recombinant fibroblast |
| 09/17/2002 | US6451302 Parenteral water-miscible non-intensely colored injectable composition of non-steroidal anti-inflammatory drugs |
| 09/17/2002 | US6451297 Powders having a granulometry of 30 to 500 microns, applicable directly to the wet hair and/or the body and surfactants |
| 09/17/2002 | US6451295 Siliconized polyamide formulated with at least one silicone material and at least one non-silicone emollient; clear products with improved structural stability and integrity |
| 09/17/2002 | US6451289 Albuterol formulations |
| 09/17/2002 | US6451288 Method of treating lung diseases with uridine 5′-diphosphate and analogs thereof |
| 09/17/2002 | US6451286 Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds |
| 09/17/2002 | US6451285 Mixture of drug, propellant and solvent |
| 09/17/2002 | US6451122 Dextrose in powder form and a process for the preparation thereof |
| 09/17/2002 | US6451020 Spine distraction implant and method |
| 09/17/2002 | US6451019 Supplemental spine fixation device and method |
| 09/17/2002 | CA2365412C Orally administrable solid ribavirin dosage forms and process for making them |
| 09/17/2002 | CA2243459C Human antibodies that bind human tnf.alpha. |
| 09/17/2002 | CA2222304C Pharmaceutical amiodarone composition for parenteral delivery |
| 09/17/2002 | CA2216700C Synergistic pharmaceutical compositions containing triamcinolone acetonide and halcinonide |
| 09/17/2002 | CA2184594C Antitussive composition containing an antitussive and benzydamine |
| 09/17/2002 | CA2180325C Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
| 09/17/2002 | CA2162604C Osteogenesis promoter and osteoporosis remedy |
| 09/17/2002 | CA2158427C Methods and compositions for controlling translation of hcv proteins |
| 09/17/2002 | CA2116674C Imidazolidyl macrolides |
| 09/17/2002 | CA2103805C Use of lacidipine for the treatment of arteriosclerosis |
| 09/17/2002 | CA2098525C Oral composition |
| 09/17/2002 | CA2085598C 1,2-dihydro-3h-dibenzisoquinoline-1,3-dione anticancer agents |
| 09/17/2002 | CA2057338C Diarylfluoromethane compounds |
| 09/17/2002 | CA2048096C N-benzyl-indoles |
| 09/17/2002 | CA2042974C Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases |
| 09/17/2002 | CA2041832C Hydrazones |
| 09/17/2002 | CA2038667C Process for the preparation of mannosyl teicoplanin derivatives and mannosyl teicoplanin aglycone |
| 09/17/2002 | CA2020431C Aqueous liquid eyedrop composition |
| 09/17/2002 | CA2019095C Bio-adhesive composition |
| 09/17/2002 | CA2014662C Anti-virals |
| 09/17/2002 | CA2007332C Use of a glycine b partial agonist as an antipsychotic |
| 09/16/2002 | CA2376844A1 Pyrazolo¢4,3-d!pyrimidin-7-ones and pyrazolo¢3,4!pyrimidin-4-ones and purinones which inhibit cgmp pdes |
| 09/16/2002 | CA2376738A1 Purine derivatives for the treatment of ischemia |
| 09/16/2002 | CA2376131A1 A method for the production of pharmaceutically active recombinant urokinase |
| 09/12/2002 | WO2002071070A2 β-ADRENOCEPTOR GENETIC POLYMORPHISMS AND OBESITY |
| 09/12/2002 | WO2002071064A1 Method of examining steroid-responsiveness |
| 09/12/2002 | WO2002070708A2 Glutamate receptor modulatory proteins and nucleic acids encoding them |
| 09/12/2002 | WO2002070654A2 Peptide deformylase inhibitors |
| 09/12/2002 | WO2002070653A2 Peptide deformylase inhibitors |
| 09/12/2002 | WO2002070563A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070562A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070561A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070560A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070559A2 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | WO2002070558A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070557A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070556A1 POLYPEPTIDE OF A P53 PROTEIN-SPECIFIC MURINE Α/β T-CELL RECEPTOR, NUCLEIC ACIDS CODING THEREFOR AND USE THEREOF |
| 09/12/2002 | WO2002070553A1 Tumour peptide antigen produced from human mdm2 proto-oncogene |
| 09/12/2002 | WO2002070552A2 POLYPEPTIDE FROM A HDM2 PROTEIN SPECIFIC MURINE Α/β T-CELL RECEPTORS, NUCLEIC ACIDS CODING FOR THE ABOVE AND USE THEREOF |
| 09/12/2002 | WO2002070544A2 Methods, compositions and kits for preserving antigenicity |
| 09/12/2002 | WO2002070541A2 Peptide deformylase inhibitors |
| 09/12/2002 | WO2002070540A2 Peptide deformylase inhibitors |
| 09/12/2002 | WO2002070537A2 Fusidic acid derivatives |
| 09/12/2002 | WO2002070534A1 C2, 8-disubstituted adenosine derivatives and their different uses |
| 09/12/2002 | WO2002070533A2 Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides |
| 09/12/2002 | WO2002070532A2 C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses |
| 09/12/2002 | WO2002070525A2 Nitrogen-based camptothecin derivatives |
| 09/12/2002 | WO2002070524A2 N-but-3-enyl norbuprenorphine and its use as analgesic |
| 09/12/2002 | WO2002070523A1 Modulators of chemokine receptor activity |
| 09/12/2002 | WO2002070522A1 Novel 2,5-diazabicyclo[2.2.1]heptane derivatives |
| 09/12/2002 | WO2002070520A1 Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands |
| 09/12/2002 | WO2002070519A1 Monobactams as cathepsin k inhibitors |
| 09/12/2002 | WO2002070518A1 Polymorphic and other crystalline forms of cis-ftc |
| 09/12/2002 | WO2002070516A2 Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors |
| 09/12/2002 | WO2002070515A2 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 09/12/2002 | WO2002070514A1 Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as ip antagonists |
| 09/12/2002 | WO2002070511A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | WO2002070510A2 Amino dicarboxylic acid derivatives with pharmaceutical properties |
| 09/12/2002 | WO2002070509A2 Antagonists of mcp-1 function and methods of use thereof |
| 09/12/2002 | WO2002070504A1 Preparation of warfarin sodium from warfarin sodium-2-propanol clathrate by solvent expulsion |
| 09/12/2002 | WO2002070502A1 Dimeric isoflavones |
| 09/12/2002 | WO2002070500A1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists |
| 09/12/2002 | WO2002070498A1 Methods for preparing new taxoids and pharmaceutical compositions containing them |
| 09/12/2002 | WO2002070496A1 Nitric oxide donors based on metallic centres |
| 09/12/2002 | WO2002070494A1 Aryl and heteroaryl urea chk1 inhibitors for use as radiosensitizers and chamosensitizers |
| 09/12/2002 | WO2002070493A1 Bisaryl derivatives having fsh receptor modulatory activity |
| 09/12/2002 | WO2002070490A1 Agonists of beta-adrenoceptors |
| 09/12/2002 | WO2002070487A1 Substituted quinolinecarboxamides as antiviral agents |
| 09/12/2002 | WO2002070486A1 Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity |
| 09/12/2002 | WO2002070485A1 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use as adenosine receptor-selective ligands |
| 09/12/2002 | WO2002070484A1 Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof |
| 09/12/2002 | WO2002070479A1 N-4-piperidinyl compounds as ccr5 modulators |
| 09/12/2002 | WO2002070478A1 Indolone derivatives having vascular-damaging activity |
| 09/12/2002 | WO2002070473A2 Carboxamide derivatives as therapeutic agents |
| 09/12/2002 | WO2002070471A1 Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours |
| 09/12/2002 | WO2002070470A2 Benzophenones as inhibitors of reverse transcriptase |